Luvox: Targeted Serotonin Reuptake Inhibition for OCD Relief
| Product dosage: 100mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 30 | $2.69 | $80.84 (0%) | 🛒 Add to cart |
| 60 | $1.95 | $161.68 $116.96 (28%) | 🛒 Add to cart |
| 90 | $1.69 | $242.52 $152.22 (37%) | 🛒 Add to cart |
| 120 | $1.58 | $323.36 $189.20 (41%) | 🛒 Add to cart |
| 180 | $1.45 | $485.04 $260.58 (46%) | 🛒 Add to cart |
| 270 | $1.36
Best per pill | $727.56 $367.22 (50%) | 🛒 Add to cart |
| Product dosage: 50mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 30 | $1.55 | $46.44 (0%) | 🛒 Add to cart |
| 60 | $1.18 | $92.88 $70.52 (24%) | 🛒 Add to cart |
| 90 | $1.05 | $139.32 $94.60 (32%) | 🛒 Add to cart |
| 120 | $0.99 | $185.76 $118.68 (36%) | 🛒 Add to cart |
| 180 | $0.93 | $278.64 $166.84 (40%) | 🛒 Add to cart |
| 270 | $0.89 | $417.96 $239.08 (43%) | 🛒 Add to cart |
| 360 | $0.86
Best per pill | $557.28 $309.60 (44%) | 🛒 Add to cart |
Synonyms | |||
Luvox (fluvoxamine maleate) is a selective serotonin reuptake inhibitor (SSRI) specifically indicated for the treatment of obsessive-compulsive disorder (OCD) in both adult and pediatric populations. As a potent and highly selective agent, it works by increasing serotonin levels in the brain, which helps regulate mood, anxiety, and obsessive thoughts. Its distinct pharmacological profile offers a valuable therapeutic option for patients who require a focused approach to managing the debilitating symptoms of OCD, with a well-established efficacy and safety record spanning decades of clinical use.
Features
- Active ingredient: Fluvoxamine maleate
- Available in 25 mg, 50 mg, and 100 mg scored tablets
- Selective serotonin reuptake inhibitor (SSRI) class
- FDA-approved for obsessive-compulsive disorder (OCD)
- Also used off-label for social anxiety disorder, depression, and panic disorder
- Requires prescription; not available over-the-counter
- Manufactured under strict pharmaceutical quality standards
Benefits
- Reduces the frequency and intensity of obsessive thoughts and compulsive behaviors
- Helps restore normal daily functioning and improves quality of life in OCD patients
- May alleviate associated symptoms of anxiety and depression
- Supports long-term management with a consistent dosing regimen
- Available in multiple strengths for individualized titration
- Backed by extensive clinical research demonstrating efficacy
Common use
Luvox is primarily prescribed for the treatment of obsessive-compulsive disorder in adults and children aged 8 years and older. It is also commonly used off-label for conditions such as social anxiety disorder, major depressive disorder, panic disorder, and post-traumatic stress disorder. Some clinicians may prescribe it for body dysmorphic disorder or eating disorders where obsessive features are prominent. Its use is always determined by a healthcare provider based on individual patient presentation, medical history, and treatment goals.
Dosage and direction
For adults with OCD, the recommended starting dose is 50 mg once daily at bedtime, which may be increased in 50 mg increments every 4–7 days as tolerated, to a maximum of 300 mg daily. Doses above 100 mg should be divided, with the larger portion administered at bedtime. For children aged 8–17, the starting dose is 25 mg daily at bedtime, with increases to a maximum of 200 mg daily (for children 8–11) or 300 mg daily (for adolescents 12–17). Tablets should be swallowed whole with water, with or without food, though taking with food may minimize gastrointestinal side effects. Dosage adjustments should only be made under medical supervision.
Precautions
Patients should be monitored for emergence of anxiety, agitation, panic attacks, insomnia, irritability, hostility, impulsivity, akathisia, hypomania, and mania, particularly during initial treatment and dose adjustments. Caution is advised in patients with a history of seizures; Luvox may lower seizure threshold. Use with care in those with hepatic impairment, as metabolism is primarily hepatic—dose reduction may be necessary. May cause hyponatremia, especially in elderly patients or those taking diuretics. Discontinuation should be gradual to avoid withdrawal symptoms. Not recommended during pregnancy unless potential benefits outweigh risks.
Contraindications
Luvox is contraindicated in patients taking monoamine oxidase inhibitors (MAOIs) or within 14 days of discontinuing MAOI therapy due to risk of serotonin syndrome. It should not be used concomitantly with thioridazine, pimozide, alosetron, or tizanidine due to potential for serious drug interactions. Contraindicated in patients with known hypersensitivity to fluvoxamine or any component of the formulation. Should not be used in patients with uncontrolled narrow-angle glaucoma.
Possible side effects
Common side effects (≥5%) include nausea, somnolence, asthenia, dizziness, nervousness, dry mouth, anorexia, constipation, sweating, abnormal ejaculation, and dyspepsia. Less frequently, insomnia, agitation, anxiety, tremor, vomiting, flatulence, vision changes, and taste perversion may occur. Rare but serious side effects include serotonin syndrome, suicidal ideation (particularly in young adults), bleeding abnormalities, angle-closure glaucoma, mania, seizures, and syndrome of inappropriate antidiuretic hormone secretion (SIADH). Most side effects are dose-dependent and often diminish with continued therapy.
Drug interaction
Luvox is a potent inhibitor of CYP1A2 and CYP2C19 enzymes and may increase plasma levels of drugs metabolized by these pathways. Significant interactions include: increased risk of serotonin syndrome with other serotonergic drugs (tramadol, fentanyl, lithium, tryptophan, St. John’s Wort); elevated levels of thioridazine, pimozide, clozapine, olanzapine, theophylline, methadone, warfarin, benzodiazepines, and some beta-blockers; reduced efficacy of tamoxifen. May enhance effects of anticoagulants and antiplatelet agents, increasing bleeding risk. Concurrent use with NSAIDs or aspirin may further increase bleeding potential.
Missed dose
If a dose is missed, it should be taken as soon as remembered unless it is close to the time for the next scheduled dose. In that case, the missed dose should be skipped and the regular dosing schedule resumed. Doubling up on doses is not recommended as it may increase the risk of side effects. Patients should maintain a consistent dosing routine and may consider using reminder tools if missing doses becomes a frequent occurrence. Consult a healthcare provider if multiple doses are missed or if uncertainty exists about how to proceed.
Overdose
Symptoms of overdose may include nausea, vomiting, diarrhea, drowsiness, dizziness, tachycardia, bradycardia, hypotension, and seizures. Serotonin syndrome manifestations (agitation, confusion, hyperthermia, hyperreflexia, incoordination) may occur in significant overdose. Fatalities have been reported with mixed overdoses involving multiple drugs. There is no specific antidote; management involves supportive care and symptomatic treatment. Gastric lavage may be considered if presented early. Activated charcoal may be administered. ECG monitoring is recommended due to potential QTc prolongation. Contact poison control center immediately for guidance.
Storage
Store at controlled room temperature (20°–25°C or 68°–77°F); excursions permitted between 15°–30°C (59°–86°F). Keep in original container, tightly closed, and protect from light and moisture. Do not store in bathroom or other humid areas. Keep out of reach of children and pets. Do not use beyond the expiration date printed on the packaging. Properly dispose of any unused medication through take-back programs or following FDA-recommended disposal methods.
Disclaimer
This information is for educational purposes only and does not constitute medical advice. Luvox is a prescription medication that should only be used under the supervision of a qualified healthcare provider. Individual response to medication may vary. Not all uses, precautions, side effects, or interactions are listed here. Patients must consult their prescribing physician for personalized medical advice and should not make changes to their treatment regimen without professional guidance. In case of medical emergency, contact emergency services immediately.
Reviews
Clinical studies have demonstrated Luvox’s efficacy in reducing Yale-Brown Obsessive Compulsive Scale (Y-BOCS) scores by approximately 40% in responsive patients. Many patients report significant reduction in obsessive thoughts and compulsive rituals within 4–6 weeks of therapeutic dosing. Some users note initial side effects that often diminish with continued use. Healthcare providers frequently appreciate its specificity for OCD and generally predictable pharmacokinetic profile. Long-term users often describe improved quality of life and functional capacity when maintained on appropriate doses. As with all SSRIs, individual responses vary, and some patients may require alternative or adjunctive therapies.